Lerer Kenneth B's Form 4 filing
Strata Critical Medical, Inc. (SRTA) · filed Jun 6, 2022
- Accession no.
- 0001779128-22-000059
- Filed
- Jun 6, 2022
- Trade date
- Jun 3-6, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $471.7K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lerer Kenneth BCIK 0001120789 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2022 | Class A common stock, $0.0001 par value per share | SSaleDisposed | −20,771 | $7.08F1 | −$147,058.68 | 294,094 | Indirect | |
| Jun 3, 2022 | Class A common stock, $0.0001 par value per share | SSaleDisposed | −11,114 | $7.08F1 | −$78,687.12 | 157,374 | Indirect | |
| Jun 6, 2022 | Class A common stock, $0.0001 par value per share | SSaleDisposed | −22,789 | $7.03F5 | −$160,206.67 | 271,305 | Indirect | |
| Jun 6, 2022 | Class A common stock, $0.0001 par value per share | SSaleDisposed | −12,195 | $7.03F5 | −$85,730.85 | 145,179 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
These transactions were executed in multiple trades at prices ranging from $7.00 to $7.29, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 2 transactions in Table I.
- F5
These transactions were executed in multiple trades at prices ranging from $7.00 to $7.16, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 2 transactions in Table I.